Needham & Company Reiterates Hold on Neurocrine (NBIX), Calls Earnings Uneventful, Does Not Expect Big Move in Stock
Tweet Send to a Friend
Needham & Company analyst Ami Fadia reiterated a Hold rating on Neurocrine Bio. (NASDAQ: NBIX) following the company's most recent ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
